Downtown Los Angeles, California
GOOD SAMARITAN HOSPITAL
Los Angeles, CA
Update on Diagnosis and Therapy
April 13, 2019
IMPORTANT CME CREDIT NOTICE
CME Certificates will be issued digitally after Speaker and Symposium Surveys are completed. Surveys are accessible after signing in with the email address you submitted during registration. Sign-in will be available 2 days prior to the conference and will also give you access to speaker slides and symposium syllabus.
March 6, 2019 is the deadline for completion of the CME Surveys.
This Live activity, 23rd Annual Heart Failure 2019: An Update on Therapy , with a beginning date of 04/13/2019 is currently being reviewed by an accrediting organization to determine credit hour awards.
This year’s program provides a comprehensive update on the prevention, diagnosis and management of heart failure (HF). The program includes lectures presented by experts combined with interactive discussion with faculty. The extensive list of topics has been selected to provide a high level, contemporary and clinically relevant update with a goal of improving the care of patients with heart failure.
At the conclusion of this activity, the participants should be able to:
- Implement effective therapy for lipid disorders
- Manage diabetes in patients with HF
- Use new FDA approved drugs for the treatment of chronic HF
- Identify new therapeutic approaches for patients with chronic HF including iron replacement
- Review effective management of the hospitalized patients with HF
- Review the clinical implications and management strategies of worsening kidney function during treatment of HF
- Assess and follow patients with HF using devices for remote hemodynamic monitoring
- Manage patients with pulmonary hypertension
- Review new information on atrial fibrillation ablation in patients with HF
- Provide an update on new biomarkers for the diagnosis and management of patients with HF
- Review mechanisms, diagnosis and management of postural tachycardia syndrome
- Select appropriate patients with severe HF due to ischemic cardiomyopathy for percutaneous and surgical revascularization
- Review results of recent trials and define indications for percutaneous mitral valve repair in patients with HF
- Review the mechanisms and hemodynamic effects of bed side circulatory assist devices for the management of severe HF and cardiogenic stroke
- Prove an update on new permanent left ventricular assist devices as a bridge to transplantation or as destination therapy
- Provide an update on the management of peripartum cardiomyopathy
- Provide guidelines for the use of palliative care for HF patients
Heart failure (HF) is common, but often unrecognized and misdiagnosed. It affects over 6 million Americans and is one of few cardiovascular disorders on the rise. An estimated 670,000 new cases are diagnosed each year and this condition is a major cause of morbidity and mortality and is the leading cause of hospitalizations of the elderly in the U.S. The importance of prevention through early identification and better treatment of risk factors such as hypertension, diabetes mellitus, obesity and lipid disorders and of education of both patients and physicians has been emphasized (Circulation 2013;128:e240).
There is strong evidence that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF ( BMC CV Disorders 2016;16:195)). Recent data continues to show that life-saving drug and devices are underutilized (Eur Heart J 2009; 30:2493, Circulation 2010; 122:585, JACC 2016; 67:1062) indicating the need for education and incorporation of recent guidelines by clinicians (Circulation 2017;136: e137).
The development of biomarkers and imaging modalities has provided clinicians with important tools for diagnosis and assessment of prognosis. There is however a great need for education regarding an effective use of these new diagnostic modalities (Nature Reviews Cardiology 2012; 9:347). HF is the leading cause of hospitalizations and management of hospitalized patients is complex and challenging (Crit Path Cardiol 2015; 14:12). Valvular heart disease is an important cause of HF and effective therapy has been underutilized (Ann Thorac Surg 2010; 90:1904).
Atrial fibrillation (AF) is common in patients with HF and is the leading cause of cardioembolic stroke. A number of new agents have been added to the therapeutic options for prevention of thromboembolic complications in patients with AF, yet in spite of their proven efficacy approximately half of eligible patients remain untreated (JACC 2016; 67:2444).
Pulmonary hypertension (PH) is a major cause of right ventricular failure and an increasing cause of death. Delayed diagnosis and underutilization of effective therapy lead to poor outcome (JACC 2015; 65:1971).
The diagnosis of cardiac amyloidosis is often delayed because the symptoms vary. It is critical to diagnose this condition early and characterize the various types of the disease which are treated differently. (Curr Probl Cardiol 2018;43:10)
Recent data have shown that drugs and devices that have been proven beneficial and are recommended in recent practice guidelines, are underutilized (JACC 2016; 67:1062), at the same time non-evidence-based implantation of expensive devices has been shown to be common (Sana M, et al JAMA 2011; 305:43). New guidelines regarding indications for resynchronization therapy are confusing and require clarifications (JACC Heart Failure 2018;308:16). Recent introduction of cardiac assist devices provides opportunity for improvement of quality of life and prolonged survival in patients with advanced HF, inappropriate and delayed referral for this procedure often results in poor outcomes (Eur J Heart Failure 2017;19:595).
Establishing educational initiatives such as this program should help to reduce practice variability, eliminate gaps between guidelines and practice and improve the outcome of patients with HF (J Clin Med Res 2014; 6:173)
This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.
It is our policy to ensure balance, independence, objectivity and scientific
rigor. All persons involved in the selection, development and presentation
of content are required to disclose any real or apparent conflicts of
interest. All conflicts of interest will be resolved prior to an educational
activity being delivered to learners through one of the following mechanisms
1) altering the financial relationship with the commercial interest, 2)
altering the individual’s control over CME content about the products
or services of the commercial interest, and/or 3) validating the activity
content through independent peer review. All persons are also required
to disclose any discussions of off label/unapproved uses of drugs or devices.
Persons who refuse or fail to disclose are disqualified from participating
in the CME activity. Participants will be asked to evaluate whether the
speaker’s outside interests reflect a possible bias in the planning
or presentation of the activity. This information is used to plan future